Assessing the risk of drug-induced neurologic disorders
Statins and neuropathy
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Clinicians are familiar with the myopathy induced by the statin class of cholesterol-lowering drugs that are now in common use. A case-control study by Gaist et al. in this issue of Neurologyshows that statins can also cause polyneuropathy.1 In itself recognition of yet another drug-induced polyneuropathy might be of little interest. But the Gaist et al. work is more generally engaging. It employs new and easily understandable methods to assess and express the risk of a drug causing neurologic side effects. Medications are responsible for a huge range of neurologic disorders, but for most such drugs we have little useful concept of risk. This makes it difficult to decide whether the neurologic disorder in a particular patient is drug-induced rather than idiopathic. If one suspects a drug side effect is due to a reversible physiologic perturbation—for instance, headache or vertigo—a trial of stopping the drug may be decisive. But no such intervention will be revealing for drugs that damage the structure of the nervous system, or permanently alter its physiology.
Our ability to obtain information about drug-induced neurologic disorders has been limited for three main reasons. First, the …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.